Clinical sudy of Kangaiping Wan on postoperative patients with colorectal cancer treated with FOLFOX chemotherapy
10.3969/j.issn.1005-1678.2017.02.028
- VernacularTitle:抗癌平丸对结直肠癌术后FOLFOX方案化疗患者的临床疗效
- Author:
Qian FANG
;
Honggen XU
;
Chunfa SHAO
;
Jin MA
- Keywords:
Kangaiping Wan;
colorectal cancer;
FOLFOX regimen
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(2):93-96
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical effect of Kangaiping Wan on postoperative patients with colorectal cancer treated by FOLFOX chemotherapy.Methods 78 cases of colorectal cancer patients admitted from February 2014 to January 2015 in our hospital were selected and divided into observation group and control group according, 39 cases in each group.The control group was treated with FOLFOX4 regimen, and the patients in the observation group were treated with Kangaiping Wan on the basis of the control group.Two groups of patients before and after treatment of immune function improvement were compared, two groups of patients with clinical efficacy, quality of life to improve the situation, adverse reactions were compared.Results After treatment, the total effective rate of the observation group was significantly higher than the control group, the difference was statistically significant (P<0.05), quality of life of the observation group was significantly higher than the control group, the difference was statistically significant (P <0.05); There were no significant differences in the rates of oral mucositis, thrombocytopenia, hemoglobin, leukocytopenia and peripheral neurotoxicity in the two groups.The diarrhea and nausea and vomiting rate in the observation group were significantly lower than those in the control group (P<0.05).Conclusion FOLFOX regimen for patients with colorectal cancer after chemotherapy, combined with Kangaiping Wan, can effectively improve the clinical symptoms and quality of life of patients and enhance the immune function ,the clinical efficacy is good and the safety is high.